⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMMX News
Immix Biopharma, Inc. Common Stock
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
globenewswire.com
IMMX
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
globenewswire.com
IMMX
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
globenewswire.com
IMMX
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
globenewswire.com
IMMX
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
globenewswire.com
IMMX
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
globenewswire.com
IMMX